A new biological triangle in cancer: Intestinal microbiota, immune checkpoint inhibitors and antibiotics

• Jie Zhang ^[1] ; Zhujiang Dai ^[1] ; Cheng Yan ^[2] ; Wenjie Zhang ^[1] ; Daorong Wang ^[3] ; Dong Tang ^[3]
  1. [1] Yangzhou University

     Yangzhou University

     China

     
  2. [2] Dalian Medical University

     Dalian Medical University

     China

     
  3. [3] Department of General Surgery, Institute of General Surgery, Clinical Medical College, Northern Jiangsu Province Hospital, Yangzhou University, Yangzhou, 225001, China

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 23, Nº. 12 (Diciembre), 2021, págs. 2415-2430
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Cancer immunotherapy has revolutionized the treatment of many malignant tumors. Although immune checkpoint inhibitors (ICIs) can reactivate the anti-tumor activity of immune cells, sensitivity to immune checkpoint inhibitor therapy depends on the complex tumor immune processes. In recent years, numerous researches have demonstrated the role of intestinal microbiota in immunity and metabolism of the tumor microenvironment, as well as the efficacy of immunotherapy. Epidemiological studies have further demonstrated the efficacy of antibiotic therapy on the probability of patients' response to ICIs and predictability of the short-term survival of cancer patients. Disturbance to the intestinal microbiota significantly affects ICIs-mediated immune reconstitution and is considered a possible mechanism underlying the development of adverse effects during antibiotic-based ICIs treatment. Intestinal microbiota, antibiotics, and ICIs have gradually become important considerations for the titer of immunotherapy. In the case of immunotherapy, the rational use of antibiotics and intestinal microbiota is expected to yield a better prognosis for patients with malignant tumors.